Altay Raises $37 Million for Oral DUX4 Program

Company Altay Therapeutics Event Type Financing (Series A) Modality Small molecule; transcription-factor inhibitor (oral) Asset DX5057 Target DUX4 Disease Area Facioscapulohumeral muscular dystrophy (FSHD) Summary Altay Therapeutics closed a $37 million Series A co-led by Sound Bioventures and HealthCap to advance DX5057, an oral small-molecule…